Novalgen Ltd.
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Subsidiary
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.novalgen.com
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
Phase 1
Recruiting
- Conditions
- Small Lymphocytic LymphomaDiffuse Large B Cell LymphomaNon-small Cell Lung Cancer (NSCLC)Mantle Cell LymphomaFollicular LymphomaChronic Lymphocytic LeukaemiaMalignant Melanoma
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- NovalGen Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04763083
- Locations
- π¬π§
University College London Hospital, London, United Kingdom
π¬π§Royal Marsden Hospital, London, United Kingdom
π¬π§The Christie NHS Foundation Trust, Manchester, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath